Brandes Investment Partners LP Purchases 7,051 Shares of Sotera Health (NASDAQ:SHC)

Brandes Investment Partners LP lifted its position in Sotera Health (NASDAQ:SHC) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,558 shares of the company’s stock after acquiring an additional 7,051 shares during the quarter. Brandes Investment Partners LP’s holdings in Sotera Health were worth $979,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SHC. Darsana Capital Partners LP lifted its holdings in Sotera Health by 716.9% during the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock valued at $334,167,000 after buying an additional 17,560,636 shares in the last quarter. Sessa Capital IM L.P. lifted its holdings in Sotera Health by 46.5% during the 3rd quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock valued at $105,220,000 after buying an additional 2,000,000 shares in the last quarter. State Street Corp lifted its holdings in Sotera Health by 18.5% during the 3rd quarter. State Street Corp now owns 4,126,806 shares of the company’s stock valued at $68,918,000 after buying an additional 644,236 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Sotera Health by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company’s stock valued at $22,308,000 after purchasing an additional 507,147 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after purchasing an additional 447,186 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Up 2.0 %

SHC stock opened at $11.59 on Friday. The firm’s fifty day simple moving average is $13.07 and its 200-day simple moving average is $14.26. The company has a market capitalization of $3.29 billion, a P/E ratio of 46.36 and a beta of 1.92. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.08.

Analyst Ratings Changes

Several research firms have recently commented on SHC. Barclays reduced their price target on shares of Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group began coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.92.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.